Investigating the effect of the Tribulus terrestris, Platanus leaves and Medicago sativa in thrombocytopenia

Investigating the effect of the combination of hydroalcoholic extracts of Tribulus terrestris, Platanus leaves and Medicago sativa on increasing production of platelets and other blood products in patients with thrombocytopenia: A Randomized Double-Blind Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230926059519N1

Enrollment

Registered

2023-10-10

Start date

2023-10-07

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenia. Thrombocytopenia, unspecified

Interventions

Intervention 1: Intervention group: The drug is taken by the patient in the form of 500 mg tablets 3 times a day (1.5 grams per day) for 7 days. The drug is a new product of Karzan DaruDarman Company

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of the patient Age between 18 and 75 years Platelet count test below 150 thousand No spontaneous bleeding No pregnancy Completing the informed consent form

Exclusion criteria

Exclusion criteria: - Reduction of platelets below 10,000 and the need for hospitalization Active bleeding

Design outcomes

Primary

Measure	Time frame
Platelet. Timepoint: The beginning of the study and 7 days later. Method of measurement: Blood test.	—

Secondary

Measure	Time frame
White blood cells. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Red blood cells. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Hemoglobin. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Neutrophil. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Lymphocyte. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Eosinophil. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Monocyte. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.	—

Measure

Time frame

White blood cells. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Red blood cells. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Hemoglobin. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Neutrophil. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Lymphocyte. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Eosinophil. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.;Monocyte. Timepoint: The beginning of the study and 7 days later. Method of measurement: Complete Blood Count test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Payandeh

Kermanshah University of Medical Sciences

m_payandeh@kums.ac.ir+98 83 3427 6300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026